Barclays Maintains Overweight on RadNet, Raises Price Target to $79
Barclays analyst Andrew Mok maintains RadNet (NASDAQ:RDNT) with a Overweight and raises the price target from $65 to $79.
Stocks · News reference
RadNet's DeepHealth Says It Received FDA 510(k) Clearance For AI-Powered Breast Ultrasound, To Roll Out Across Network Covering Over 700,000 Studies Annually By Year-End
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — RadNet, Inc. (RDNT)
Filed: 2026-08-14 AccNo: 0001683168-26-006479 Size: 208 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Truist Securities Maintains Buy on RadNet, Raises Price Target to $94
Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:RDNT) with a Buy and raises the price target from $90 to $94.
RadNet shares are trading higher after the company reported better-than-expected Q2 financial results.